KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma

被引：0
|
作者：
Atkins, Michael B.
Carlino, Matteo S.
Hill, Andrew G.
McNeil, Catriona M.
Long, Georgina V.
Atkinson, Victoria
Cebon, Jonathan S.
Jameson, Michael B.
Hwu, Wen-Jen
Thompson, John A.
Anderson, James
Moreno, Blanca Homet
Ibrahim, Nageatte
Ribas, Antoni
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT065
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
    T. M. L. Tong
    M. K. van der Kooij
    F. M. Speetjens
    A. R. van Erkel
    R. W. van der Meer
    J. Lutjeboer
    E. L. van Persijn van Meerten
    C. H. Martini
    R. W. M. Zoethout
    F. G. J. Tijl
    C. U. Blank
    M. C. Burgmans
    E. Kapiteijn
    Trials, 23
  • [42] Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.
    Tong, Thais M. L.
    Burgmans, Mark C.
    Van der Kooij, Monique
    Speetjens, Frank M.
    van Erkel, Arian R.
    van der Meer, Rutger W.
    van den Bosch, Shelley
    Jonker, Mare A.
    Roozen, Inge C. F. M.
    Lutjeboer, Jacob
    Rijksen, Fenna
    van Persijn-van Meerten, Els L.
    Martini, Chris H.
    Zoethout, Remco W. M.
    Tijl, Fred G. J.
    Blank, Christian U.
    Kapiteijn, Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
    Tong, T. M. L.
    van der Kooij, M. K.
    Speetjens, F. M.
    van Erkel, A. R.
    van der Meer, R. W.
    Lutjeboer, J.
    van Meerten, E. L. van Persijn
    Martini, C. H.
    Zoethout, R. W. M.
    Tijl, F. G. J.
    Blank, C. U.
    Burgmans, M. C.
    Kapiteijn, E.
    TRIALS, 2022, 23 (01)
  • [44] Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).
    Hodi, F. Stephen
    Postow, Michael Andrew
    Chesney, Jason Alan
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth F.
    McDermott, David F.
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv
    Shaheen, Montaser F.
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April K.
    Taylor, Matthew H.
    Ott, Patrick Alexander
    Jiang, Joel
    Gagnier, Paul
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).
    Hsieh, David
    Kainthla, Radhika
    Zhu, Hao
    Beg, Muhammad S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 584 - 584
  • [46] Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
    Puzanov, Igor
    Dummer, Reinhard
    Schachter, Jacob
    Pavlick, Anna C.
    Gonzalez, Rene
    Ascierto, Paolo Antonio
    Margolin, Kim Allyson
    Hamid, Omid
    Agarwala, Sanjiv S.
    Carlino, Matteo S.
    Utikal, Jochen
    Lotem, Michal
    Ribas, Antoni
    Mohr, Peter
    Roach, Charlotte M.
    Dolled-Filhart, Marisa
    Li, Xiaoyun Nicole
    Ebbinghaus, Scot
    Kang, Soonmo Peter
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO plus IPI) combination therapy in advanced melanoma
    Larkin, J. M. G.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Rutkowski, P.
    Lao, C.
    Cowey, C. L.
    Schadendorf, D.
    Wagstaff, J.
    Dummer, R.
    Ferrucci, P. F.
    Smylie, M.
    Hogg, D.
    Hill, A.
    Marquez-Rodas, I.
    Haanen, J. B. A. G.
    Rizzo, J.
    Balogh, A.
    Hodi, F. S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 904 - 905
  • [48] Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response
    Zoe Quandt
    Saya Jacob
    Muhammad Zaki Hidayatullah Fadlullah
    Chaorong Wu
    Clinton Wu
    Laura Huppert
    Lauren S. Levine
    Paula Sison
    Katy K. Tsai
    Melissa Chow
    Jee Hye Kang
    Jimmy Hwang
    James C. Lee
    Ariel Oglesby
    Jessica Venegas
    Ben J. Brintz
    Aik Choon Tan
    Mark S. Anderson
    Michael D. Rosenblum
    Arabella Young
    Adil I. Daud
    BJC Reports, 2 (1):
  • [49] KEYNOTE-151: A phase Ib study of second-line pembrolizumab (Pembro) for Chinese patients (pts) with advanced or metastatic melanoma
    Si, L.
    Zhang, X.
    Shu, Y.
    Pan, H.
    Wu, D.
    Liu, J.
    Lou, F.
    Wang, X.
    Wen, X.
    Gu, Y.
    Zhu, L.
    Lan, S.
    Cai, X.
    Zhou, Y.
    Ge, J.
    Li, J.
    Wu, H.
    Guo, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer
    Powles, Thomas
    Gschwend, Juergen E.
    Loriot, Yohann
    Bellmunt, Joaquim
    Geczi, Lajos
    Vulsteke, Christof
    Abdelsalam, Mahmoud
    Gafanov, Rustem
    Bae, Woo Kyun
    Revesz, Janos
    Yamamoto, Yoshiaki
    Anido, Urbano
    Su, Wen-Pin
    Fleming, Mark T.
    Markus, Maurice
    Feng, Dai
    Poehlein, Christian Heinrich
    Alva, Ajjai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345